Avinger Invests In Trials Of Lumivascular Peripheral Atherectomy Device As Company Restructures

US FDA-approval for an in-stent restenosis trial of Avinger's Pantheris atherectomy system comes on the heels of positive results from the VISION trial of the Pantheris in patients with peripheral arterial disease of the lower extremities. Meanwhile, the company is restructuring to cut its expenses by half as its stock has been stuck below a dollar a share since April.

MT1706_Pantheris-Atherectomy-Catheter_1200
Avinger's Pantheris Directional Atherectomy System • Source: Avinger, Inc.

Avinger Inc. is counting on the growing evidence base supporting its flagship Pantheris directional atherectomy system, along with forthcoming upgrades to the device, to revive the company's revenues and sagging stock price.

Pantheris is built on Avinger's unique Lumivascular technology, which allows a laser-imaging system to be mounted on a catheter tool that removes material blocking an artery. "The technology is centered...

More from Cardiology

More from Device Area